Our #RAREis Commitment

With more than 7,000 known rare diseases impacting over 400 million people worldwide, the need for rare disease innovation is significant. As part of our ongoing mission, we are committed to advancing and improving the experience of living with a rare disease by making a meaningful difference for the people and communities we serve.

To further support the rare disease community, we are excited to announce the launch of the #RAREis Global Advocate Grant, a new program designed to support the rare disease community by providing financial assistance to U.S. and global patient advocacy groups working to advance, educate and address the needs of the community.

The #RAREis Global Advocate Grant will support 30 groups addressing the needs of the rare disease community through support programs and disease education initiatives. With a $150,000 commitment in 2022, each group will be eligible to receive a one-time $5,000 grant.

“Horizon’s approach is to listen, learn and understand the challenges of the rare disease community, ultimately working to help patients get better educated, engage with each other and seek the best possible care,” said Matt Flesch, vice president, communications and patient advocacy, Horizon. “Finding new ways to support the community is the driving force behind what we do each day, and the #RAREis Global Advocate Grant will help many smaller rare non-profit organizations better educate and engage their communities.”

Apply Today!

Applications are open from Monday, May 2 to Friday, June 3, 2022. To qualify for consideration, an organization must:

  • Be considered a non-profit
  • Be focused on supporting the rare disease community, outside of all Horizon’s disease states
  • Use all funds in 2022
  • Not be associated with healthcare providers

Visit RAREisCommunity.com/Grant for more information and to apply. Recipients will be announced in June and grants will be provided in July 2022.

You are Leaving RAREisCommunity.com

You are now leaving the #RAREis™ Community website. Amgen is not responsible for content or availability of third-party sites.

Return to RAREisCommunity.com OK, Continue X